The initiation of coverage by HC Wainwright & Co. with a Buy rating and a specific price target of $3 suggests a strong positive outlook for Cyclo Therapeutics. This endorsement by a reputable analyst can lead to increased investor interest and potentially drive the stock price up in the short term.